Back

Effects on cardiotoxicity of CT-P6 Biosimilars vs Trastuzumab among adults with breast cancer: a systematic review and meta-analysis

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology: global clinical challenges Cardio-Oncology ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Ferdinand Santoceldes

Saint Lukes Medical Center Global City, Taguig (Philippines)

6 More presentations in this session

Presentation thumbnail
Elevated remnant cholesterol and increased risk of colorectal cancer and atherosclerotic cardiovascular diseases: a prospective cohort study
Miss Y. Xiao (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Effects of chemoradiotherapy on the cardiac and aortic glucose metabolism in patients with advanced non-small cell lung cancer
Doctor P. Khaing (Edinburgh, GB)
Abstract Slides Video
Presentation thumbnail
Practical value and external validation of the PRECISE-DAPT cancer score in patients with acute myocardial infarction
Doctor M. Dafaalla (Stoke-on-Trent, GB)
Abstract Slides Video
Presentation thumbnail
Real-world analysis of risk factors for cardiovascular toxicity associated with immune checkpoint inhibitors
Professor R. Asteggiano (Turin, IT)
Abstract Slides Video
Presentation thumbnail
Immune checkpoint inhibitor associated myocarditis - lessons from a case series
Mrs M. Prieto (Dresden, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Cardio-oncology: global clinical challenges

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Cardioprotective role of statins in breast cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis
thumbnail
Congress Presentation
The risks of continuing trastuzumab treatment in HER-2 positive breast cancer after the development of asymptomatic left ventricular dysfunction
thumbnail
Congress Presentation
New onset of left ventricular dysfunction and diastolic dysfunction are uncommon in patients with her2+ breast cancer after completion of cancer therapy.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources